Aim: To determine whether heart rate variability parameters vary between in-utero drug-exposed infants and controls. To determine correlations between Finnegan score and heart rate variability parameters. To differentiate those drug-exposed infants who require treatment from those infants who do not.
Methods: A total of 24 jaundiced control subjects and 25 in-utero drug-exposed infants were enrolled. The Finnegan score and an electrocardiographic rhythm strip were obtained at 4-h intervals. RR intervals (time between consecutive R waves) were manually tabulated from the rhythm strip and analyzed. Time-domain heart rate variability parameters were calculated and analyzed for both groups.
Results: Heart rate variability parameters were cumulatively lower over 3 days in in-utero drug-exposed infants compared with controls (p < 0.05). Root mean square of differences of standard deviation of RR intervals on first day of life, and standard deviation of RR intervals, percentage of consecutive RR intervals greater than 50 ms, and root mean square of differences of standard deviation of RR intervals on the second day of life were significantly lower between in-utero drug-exposed infants and control infants. Three out of five parameters were significantly lower in in-utero drug-exposed infants pre-treatment versus post-treatment (p = 0.001, p = 0.0001, and p = 0.021, respectively). Root mean square of differences of standard deviation of RR intervals was able to differentiate in-utero drug-exposed infants requiring opiate therapy and in-utero drug-exposed infants that did not (p = 0.02).
Conclusion: Heart rate variability analysis can contribute to the management of in-utero drug-exposed infants. Heart rate variability could be used in dose titration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607234 | PMC |
| http://dx.doi.org/10.1177/2050312114556525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.
J Allergy Clin Immunol Pract
November 2024
Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif.
Background: After introducing IL-1/IL-6 inhibitors, some patients with Still and Still-like disease developed unusual, often fatal, pulmonary disease. This complication was associated with scoring as DReSS (drug reaction with eosinophilia and systemic symptoms) implicating these inhibitors, although DReSS can be difficult to recognize in the setting of systemic inflammatory disease.
Objective: To facilitate recognition of IL-1/IL-6 inhibitor-DReSS in systemic inflammatory illnesses (Still/Still-like) by looking at timing and reaction-associated features.
Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial.
AIDS
July 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: IMPAACT 1077BF/FF (PROMISE) compared the safety/efficacy of two HIV antiretroviral therapy (ART) regimens to zidovudine (ZDV) alone during pregnancy for HIV prevention. PROMISE found an increased risk of preterm delivery (<37 weeks) with antepartum triple ART (TDF/FTC/LPV+r or ZDV/3TC/LPV+r) compared with ZDV alone. We assessed the impact of preterm birth, breastfeeding, and antepartum ART regimen on 24-month infant survival.
View Article and Find Full Text PDFInfant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data.
Pharmaceutics
April 2023
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Clinical Pharmacology and Toxicology, Charitéplatz 1, 10117 Berlin, Germany.
Infants of mothers treated for tuberculosis might be exposed to drugs via breast milk. The existing information on the exposure of breastfed infants lacks a critical review of the published data. We aimed to evaluate the quality of the existing data on antituberculosis (anti-TB) drug concentrations in the plasma and milk as a methodologically sound basis for the potential risk of breastfeeding under therapy.
View Article and Find Full Text PDFMaternal opioid addiction: A potential cause of elevated 17-OH progesterone in neonatal screening.
Arch Pediatr
February 2023
CHRU Nancy, Department of Pediatrics, 54500, Vandoeuvre Les Nancy, France; Université de Lorraine, Inserm 1256, N-GERE Nutrition Genetics and Environmental Risks, 54500, Vandoeuvre les Nancy, France. Electronic address:
Article Synopsis
- The study investigates how maternal drug consumption during pregnancy affects 17-hydroxyprogesterone (17-OHP) levels in newborns, as high levels can lead to false positives in neonatal screening for congenital adrenal hyperplasia (CAH).
- Researchers analyzed data from term newborns born at the Maternity Hospital of Nancy between 2002 and 2018, comparing 17-OHP levels and birth outcomes between drug-exposed infants and those born to mothers without drug addiction.
- Findings showed that drug-exposed newborns had significantly higher 17-OHP levels (9.83 nmol/L) compared to controls (4.90 nmol/L), along with smaller size and lower Ap
Development and Implementation of State and Federal Child Welfare Laws Related to Drug Use in Pregnancy.
Milbank Q
December 2022
Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, United States.
Unlabelled: Policy Points Over the past several decades, states have adopted policies intended to address prenatal drug use. Many of these policies have utilized existing child welfare mechanisms despite potential adverse effects. Recent federal policy changes were intended to facilitate care for substance-exposed infants and their families, but state uptake has been incomplete.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!